The Last Signature Before the Infusion: Inside the UK QP Batch Release Bottleneck
One signature, a lot of weight
In a cell-and-gene therapy suite, everybody gets excited about the science. The vector titre. The transduction efficiency. The clean sterility run. Then someone asks the question that decides whether the batch actually moves: has the QP signed it off?
The Qualified Person — usually shortened to QP — is the named person who certifies a batch for release. In the UK, that means confirming the batch was manufactured and checked in line with its licence, clinical trial authorisation or specials framework, and that it is fit for its intended use. No QP certification, no batch. It really is that blunt.
For small advanced therapy medicinal product (ATMP) manufacturers, that single role can turn into a bottleneck. Not because QPs enjoy being awkward, but because the evidence pack they need is broad, detailed and unforgiving.
What the QP is actually checking
A QP is not just signing the certificate of analysis. They are making a professional judgement across the batch record. In practice, they will want to see:
- Starting materials and raw materials: identity, grade, supplier qualification, certificates of analysis, and evidence that anything animal-derived or human-derived was sourced appropriately.
- Chain of identity and chain of custody: especially for autologous therapies. If the cells could belong to the wrong patient, everything else is noise.
- Manufacturing record: executed batch record, critical process parameters, in-process checks, deviations, and any reprocessing or out-of-specification events.
- Facility and environmental data: viable and non-viable particle monitoring, cleanroom qualification status, and any excursions that could affect product quality.
- Quality control release testing: sterility, mycoplasma, endotoxin, identity, purity, potency and any product-specific assays. Where rapid or alternative methods are used, the validation story needs to be clear.
- Validation and qualification: process validation, analytical method validation, shipping validation and, for ATMPs, often comparability data if something has changed.
- Quality management system records: deviations, change controls, complaints, OOS investigations and CAPA status.
The QP is also checking that the batch record tells a coherent story. Gaps are not automatically fatal, but unexplained gaps are. A missing signature, an unclosed deviation or a supplier certificate that does not match the material used will all slow the release down.
UK versus EU-facing teams: the practical difference
Since Brexit, the UK and EU QP systems have diverged in practice. A UK QP certifies batches for the UK market or UK clinical trials. An EU QP is needed for EU release. For companies running both UK and EU studies, that can mean two release pathways, two sets of batch record expectations and two QP declarations — even when the manufacturing is identical.
The paperwork may look similar, but the practical friction is real. UK-facing teams need to keep their QP eligibility and declarations aligned with MHRA expectations. EU-facing teams need an EU QP who can certify under EU rules. Smaller manufacturers often have one quality team trying to satisfy both, which is where release timelines start to stretch.
There is also a subtler issue: the UK QP has to be satisfied with the evidence, not just the template. If a company has grown quickly and its batch records are a patchwork of legacy formats, the QP review can become an archaeological dig. That is not a regulatory failure by itself, but it is a bottleneck.
Where small ATMP teams get stuck
In small companies, the QP is often part-time, external or shared across sites. That works fine when the evidence pack is clean. It becomes painful when the QP review happens late and the quality team is still chasing supplier certificates, deviation closures or shipping validation reports.
Three common sticking points stand out:
- Late QP involvement. If the QP first sees the batch record after the final QC result, every gap becomes urgent. Bring them in earlier — at least for critical deviations and change controls.
- Weak chain-of-identity documentation. Autologous products live or die on identity. If the paperwork relies on memory and WhatsApp, the QP will not be impressed.
- Shipping and thaw validation. A batch can be perfect in the cleanroom and still fail release because the cold-chain or thaw process is not properly validated for the intended clinical site.
A pre-release checklist that saves a week
This is not a substitute for your own quality system, but it is the kind of practical list that helps early-career scientists and lab managers avoid a last-minute scramble:
- Confirm the batch record is complete, legible and signed at every critical step.
- Check that every deviation has a documented impact assessment and a clear closure status.
- Match raw material certificates to the actual lot numbers used.
- Verify chain-of-identity and chain-of-custody records against the patient or donor identifiers.
- Confirm environmental monitoring results are within limits, or that excursions have a documented risk assessment.
- Check that QC release testing is complete, validated and reviewed by the right person.
- Confirm shipping validation and thaw instructions are available for the receiving clinical site.
- Make sure change controls affecting the batch have been assessed and approved before release.
- Give the QP a clean index: batch record, QC summary, deviation log, validation status and declaration draft.
The takeaway
The QP is not a rubber stamp, and that is the point. For UK cell-and-gene therapy manufacturers, the QP is the last real checkpoint between a promising batch and a patient. Small teams can either treat that as a late-stage hurdle or build it into the manufacturing rhythm from day one.
The labs that do the latter tend to release faster — not because their science is easier, but because their evidence is ready when the signature is needed.
